Parameter | Estimate | RSE (%) | BSV (CV%) | RSE (%) |
---|---|---|---|---|
Crenezumab | ||||
CLel (L/day) | 0.159 | 3.0 | 19.1 | 8.4 |
CLint (L/day) | 1.01 | 5.8 | 15.3 | 25 |
Vcent (L) | 2.89 | 3.4 | 18.3 | 8.8 |
Vperiph (L) | 1.84 | 10 | 75.2 | 9.7 |
Q (L/day) | 0.142 | 4.8 | – | – |
Fsc (%) | 66.2 | 3.9 | – | – |
Ka (/day) | 0.161 | 6.4 | – | – |
Kd Aβ(1–40) (nM) | 12.0 | 3.0 | 13.6a | 12 |
Kd Aβ(1–42) (nM) | 9.37 | 2.5 | 13.6a | 12 |
BWT (kg) on CLel | 0.835 | 12 | – | – |
BWT (kg) on CLint | 0.474 | 42 | – | – |
BWT (kg) on Vcent | 0.725 | 17 | – | – |
Aβ(1–40) | ||||
Baseline (pM) | 142 | 1.3 | 8.3 | 10 |
Kdeg (/day) | 114 | 5.7 | 17.9a | 12 |
Q (L/day) | 8.72 | 31 | – | – |
Vperiph (L) | 3.77 | 11 | – | – |
Age (year) on baseline | 0.0037 | 27 | ||
GFR (mL/min/1.73 m2) on baseline | − 0.0035 | 20 | ||
Sex (male) on Kdegb | − 0.16 | 36 | ||
Aβ(1–42) | ||||
Baseline (pM) | 5.98 | 1.7 | 13.8 | 9.9 |
Kdeg (/day) | 287 | 6.5 | 17.9a | 12 |
Q (L/day) | 229 | 15 | – | – |
Vperiph (L) | 8.19 | 7.8 | – | – |
GFR (mL/min/1.73 m2) on baseline | − 0.0048 | 22 | ||
Sex (male) on Kdegb | − 0.16 | 36 |